Roche Holding Cancer Drug Trial Succeeds Two Years Early

A late-stage clinical trial of cancer drug MabThera for treating the relapsed indolent form of non-Hodgkin's lymphoma met its primary goals two years earlier than expected, Roche Holding AG (ROG.VX: Quote, Profile, Research) said on Tuesday.
MORE ON THIS TOPIC